Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $6.1 million.

  • Lexaria Bioscience's Liabilities and Shareholders Equity fell 3821.78% to $6.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was $25.6 million, marking a year-over-year decrease of 2393.48%. This contributed to the annual value of $4.2 million for FY2025, which is 5291.81% down from last year.
  • Lexaria Bioscience's Liabilities and Shareholders Equity amounted to $6.1 million in Q4 2025, which was down 3821.78% from $4.2 million recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Liabilities and Shareholders Equity ranged from a high of $13.3 million in Q3 2021 and a low of $3.1 million during Q3 2023
  • For the 5-year period, Lexaria Bioscience's Liabilities and Shareholders Equity averaged around $7.8 million, with its median value being $8.3 million (2022).
  • In the last 5 years, Lexaria Bioscience's Liabilities and Shareholders Equity skyrocketed by 51284.1% in 2021 and then plummeted by 7241.26% in 2023.
  • Lexaria Bioscience's Liabilities and Shareholders Equity (Quarter) stood at $11.7 million in 2021, then plummeted by 49.91% to $5.9 million in 2022, then crashed by 42.98% to $3.4 million in 2023, then soared by 191.97% to $9.8 million in 2024, then crashed by 38.22% to $6.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $6.1 million for Q4 2025, versus $4.2 million for Q3 2025 and $6.7 million for Q2 2025.